Publication: 2870

Publication: 2870

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

PubMed

DOI

Google Scholar

Citation:: J Clin Oncol vol 25 (29) 4569-74

Year:: 2007
Type:: Manuscript
Funding:: NCTN
Endpoint:: No-Endpoint
Analysis:: Other
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: Yes
Book Volume:

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:
Grants:: CA25224

Corr. Author:
Authors:: Daniel J Sargent Smitha Patiyil Greg Yothers Daniel G Haller Richard Gray Jacqueline Benedetti Marc Buyse Roberto Labianca Jean Francois Seitz Christopher J O'Callaghan Guido Francini Axel Grothey Michael O'Connell Paul J Catalano David Kerr Erin Green Harry S Wieand Richard M Goldberg Aimery de Gramont

Networks:

Study: ACCENT
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: N/A

Keywords:: Aged, Chemotherapy, Adjuvant, Clinical Trials, Phase III as Topic, Colonic Neoplasms, Colorectal Neoplasms, Data Interpretation, Statistical, Disease-Free Survival, Female, Humans, Male, Middle Aged, Proportional Hazards Models, Randomized Controlled Trials as Topic, Recurrence, Time Factors, Treatment Outcome